Ignite Creation Date:
2025-12-25 @ 12:12 AM
Ignite Modification Date:
2025-12-28 @ 7:17 PM
Study NCT ID:
NCT05169658
Status:
COMPLETED
Last Update Posted:
2025-04-11
First Post:
2021-12-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
Sponsor:
University of Washington
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-23
Start Date Type:
ACTUAL
Primary Completion Date:
2025-04-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-04-02
Completion Date Type:
ACTUAL
First Submit Date:
2021-12-09
First Submit QC Date:
None
Study First Post Date:
2021-12-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-09
Last Update Post Date:
2025-04-11
Last Update Post Date Type:
ACTUAL